![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C28H22Cl3N3O5 |
Molar mass | 586.85 g·mol−1 |
3D model (JSmol) | |
| |
|
Cilofexor (also known as GS-9674) is a nonsteroidal farnesoid X receptor (FXR) agonist in clinical trials for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH),[1][2][3] and primary sclerosing cholangitis (PSC).[4][5] It is being investigated for use alone or in combination with firsocostat, selonsertib,[1]orsemaglutide.[2][6] In rat models[3] and human clinical trials[7] of NASH it has been shown to reduce fibrosis and steatosis, and in human clinical trials of PSC it improved cholestasis and reduced markers of liver injury.[4]
It is being developed by the pharmaceutical company Gilead Sciences.[8][6]